Outcome of Transplantation for Myelofibrosis

Karen K. Ballen; Smriti Shrestha; Kathleen A. Sobocinski; Mei-Jie Zhang; Asad Bashey; Brian J. Bolwell; Francisco Cervantes; Steven M. Devine; Robert Peter Gale; Vikas Gupta; Theresa E. Hahn; William J. Hogan; Nicolaus Kroeger; Mark R. Litzow; David I. Marks; Richard T. Maziarz; Philip L. McCarthy; Gary J. Schiller; Harry C. Schouten; Vivek Roy; Peter H. Wiernik; Mary M. Horowitz; Sergio A. Giralt; Mukta Arora

doi:10.1016/j.bbmt.2009.10.025

Outcome of Transplantation for Myelofibrosis

Karen K. Ballen^*, Smriti Shrestha, Kathleen A. Sobocinski, Mei-Jie Zhang, Asad Bashey, Brian J. Bolwell, Francisco Cervantes, Steven M. Devine, Robert Peter Gale, Vikas Gupta, Theresa E. Hahn, William J. Hogan, Nicolaus Kroeger, Mark R. Litzow, David I. Marks, Richard T. Maziarz, Philip L. McCarthy, Gary J. Schiller, Harry C. Schouten, Vivek RoyPeter H. Wiernik, Mary M. Horowitz, Sergio A. Giralt, Mukta Arora

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010)

Original language	English
Pages (from-to)	358-367
Journal	Biology of Blood and Marrow Transplantation
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.bbmt.2009.10.025
Publication status	Published - Mar 2010

Keywords

Myelofibrosis
Allogeneic transplantation

Access to Document

10.1016/j.bbmt.2009.10.025Licence: CC BY-NC-ND

Cite this

Ballen, K. K., Shrestha, S., Sobocinski, K. A., Zhang, M.-J., Bashey, A., Bolwell, B. J., Cervantes, F., Devine, S. M., Gale, R. P., Gupta, V., Hahn, T. E., Hogan, W. J., Kroeger, N., Litzow, M. R., Marks, D. I., Maziarz, R. T., McCarthy, P. L., Schiller, G. J., Schouten, H. C., ... Arora, M. (2010). Outcome of Transplantation for Myelofibrosis. Biology of Blood and Marrow Transplantation, 16(3), 358-367. https://doi.org/10.1016/j.bbmt.2009.10.025

@article{a49a44b9c80b45188f78fa8c61c1f560,

title = "Outcome of Transplantation for Myelofibrosis",

abstract = "Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010) ",

keywords = "Myelofibrosis, Allogeneic transplantation",

author = "Ballen, {Karen K.} and Smriti Shrestha and Sobocinski, {Kathleen A.} and Mei-Jie Zhang and Asad Bashey and Bolwell, {Brian J.} and Francisco Cervantes and Devine, {Steven M.} and Gale, {Robert Peter} and Vikas Gupta and Hahn, {Theresa E.} and Hogan, {William J.} and Nicolaus Kroeger and Litzow, {Mark R.} and Marks, {David I.} and Maziarz, {Richard T.} and McCarthy, {Philip L.} and Schiller, {Gary J.} and Schouten, {Harry C.} and Vivek Roy and Wiernik, {Peter H.} and Horowitz, {Mary M.} and Giralt, {Sergio A.} and Mukta Arora",

year = "2010",

month = mar,

doi = "10.1016/j.bbmt.2009.10.025",

language = "English",

volume = "16",

pages = "358--367",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Science",

number = "3",

}

Ballen, KK, Shrestha, S, Sobocinski, KA, Zhang, M-J, Bashey, A, Bolwell, BJ, Cervantes, F, Devine, SM, Gale, RP, Gupta, V, Hahn, TE, Hogan, WJ, Kroeger, N, Litzow, MR, Marks, DI, Maziarz, RT, McCarthy, PL, Schiller, GJ, Schouten, HC, Roy, V, Wiernik, PH, Horowitz, MM, Giralt, SA & Arora, M 2010, 'Outcome of Transplantation for Myelofibrosis', Biology of Blood and Marrow Transplantation, vol. 16, no. 3, pp. 358-367. https://doi.org/10.1016/j.bbmt.2009.10.025

TY - JOUR

T1 - Outcome of Transplantation for Myelofibrosis

AU - Ballen, Karen K.

AU - Shrestha, Smriti

AU - Sobocinski, Kathleen A.

AU - Zhang, Mei-Jie

AU - Bashey, Asad

AU - Bolwell, Brian J.

AU - Cervantes, Francisco

AU - Devine, Steven M.

AU - Gale, Robert Peter

AU - Gupta, Vikas

AU - Hahn, Theresa E.

AU - Hogan, William J.

AU - Kroeger, Nicolaus

AU - Litzow, Mark R.

AU - Marks, David I.

AU - Maziarz, Richard T.

AU - McCarthy, Philip L.

AU - Schiller, Gary J.

AU - Schouten, Harry C.

AU - Roy, Vivek

AU - Wiernik, Peter H.

AU - Horowitz, Mary M.

AU - Giralt, Sergio A.

AU - Arora, Mukta

PY - 2010/3

Y1 - 2010/3

N2 - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010)

AB - Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010)

KW - Myelofibrosis

KW - Allogeneic transplantation

U2 - 10.1016/j.bbmt.2009.10.025

DO - 10.1016/j.bbmt.2009.10.025

M3 - Article

SN - 1083-8791

VL - 16

SP - 358

EP - 367

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 3

ER -

Outcome of Transplantation for Myelofibrosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this